Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery
Phase II, single-arm, prospective clinical study of Toripalimab(a PD-1 antibody) combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery.
Malignant Melanoma|Sinonasal Melanoma
PROCEDURE: endoscopic surgery
Overall survival, 3 year Overall Survival rate, From date of first treatment until the date of death from any cause,through study completion,up to 3 years.]
progression free survival, the date of first treatment to the first recording of disease progression or death from any cause., From date of first treatment until the date of first documented progression or date of death from any cause, whichever came firstï¼Œthrough study completion,up to 3 years.
Local progression free survival, the date of first treatment to local failure or death, From date of first treatment to local failure or date of death from any cause,through study completion,up to 3 years.|Regional progression free survival, the date of first treatment to regional failure or death, From date of first treatment to regional failure or date of death from any cause, through study completion,up to 3 years.|Distant metastasis free survival, the date of first treatment to distant metastasis or death, From date of first treatment to distant metastasis or date of death from any cause, through study completion,up to 3 years.]|Toxicities, Using CTCAE Version5.0 to evaluate, From date of first treatment through study completion,up to 3 years.
Phase II, single-arm, prospective clinical study of Toripalimab(a PD-1 antibody) combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery.